Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 222 results found since Jan 2013.
Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 to 2017
CONCLUSIONS: In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with hematological cancer and the most common cause of admission is heart failure.PMID:35913736 | DOI:10.1093/ehjqcco/qcac045
Source: Clinical Prostate Cancer - August 1, 2022 Category: Cancer & Oncology Authors: Ofer Kobo Zahra Raisi-Estabragh Sofie Gevaert Jamal S Rana Harriette G C Van Spall Ariel Roguin Steffen E Petersen Bonnie Ky Mamas A Mamas Source Type: research
NaF-PET shows bone formation in psoriatic arthritis patients
F-18 sodium fluoride (NaF) PET/CT may be a valuable tool for imaging patient...Read more on AuntMinnie.comRelated Reading:
NaF-PET reveals aortic wall injuries
NaF-PET scans reveal plaque -- and possible risk of stroke
NaF-PET/CT does well in detecting prostate metastases
NaF-PET/CT rarely finds prostate cancer bone metastases
AI algorithm can classify bone lesions on PET/CT images
Source: AuntMinnie.com Headlines - November 18, 2022 Category: Radiology Source Type: news
Not all patients get necessary CT for suspected acute aortic syndrome
Do all patients with suspected acute aortic syndrome get CT aortography fo...Read more on AuntMinnie.comRelated Reading:
Breast cancer death rates may be declining, but not for Black women
CT screening evens out gender disparity in lung cancer mortality
Are all men benefiting from preop MRI for prostate cancer surgery?
Disparities remain in neuroimaging utilization for stroke
Structural racism causes disparities in prostate MRI use
Source: AuntMinnie.com Headlines - November 18, 2022 Category: Radiology Source Type: news
Recognizing the True Value of Testosterone Therapy in Health Care
Androg Clin Res Ther. 2022 Dec 28;3(1):217-223. doi: 10.1089/andro.2022.0021. eCollection 2022.ABSTRACTThere has been little recognition within the medical community of the health impact of testosterone (T) deficiency (TD), also known as hypogonadism, and the substantial benefits of testosterone therapy (TTh) on health and quality of life despite high-level clinical evidence. In a roundtable symposium, investigators summarized the contemporary evidence in several key clinical areas. TD negatively impacts human health and quality of life and is associated with increased mortality. Several studies have demonstrated that TTh ...
Source: Clinical Prostate Cancer - January 16, 2023 Category: Cancer & Oncology Authors: Abraham Morgentaler Abdulmaged Traish Rajat S Barua Paresh Dandona Sandeep Dhindsa Mohit Khera Farid Saad Source Type: research
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
CONCLUSIONS: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.PMID:36791755 | DOI:10.6004/jnccn.2022.7083
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 15, 2023 Category: Cancer & Oncology Authors: Alice Dragomir Nawar Touma Jason Hu Sylvie Perreault Armen G Aprikian Source Type: research
